Compound diisopropylamine dichloroacetate for injection
Function and Efficacy
1. Effects on fatty liver (1) Consuming liver fat: This product is decomposed into diisopropylamine and dichloroacetic acid in the body. The former generates methionine under the activation of ATP, and the latter is metabolized to glycine. Under the action of glycine lyase, N5N10-CH2-FH4 (methyltetrahydrofolate) is generated, which provides energy at the same time. Both can provide methyl groups to promote choline synthesis. Choline reacts with liver fat to generate lecithin, which promotes the decomposition of liver fat. (2) Transporting liver fat: Lecithin, liver fat, and cholesterol combine with apolipoproteins to form lipoproteins. Lipoproteins are easily soluble in plasma, thereby transporting fat from the liver to the outside of the liver and reducing the accumulation of fat in the liver. (3) This product can reduce arterial blood
Ingredients
This product is a compound preparation of diisopropylamine dichloroacetate and sodium gluconate, and its composition is: each bottle contains 40 mg of diisopropylamine dichloroacetate and 38 mg of sodium gluconate.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Diisopropylammonium dichloroacetateIngredients |
It is broken down into diisopropylamine and dichloroacetic acid in the body. The former produces methionine, and the latter is metabolized to glycine. Under the action of glycine lyase, it produces N5N10-CH2-FH4 (methyltetrahydrofolate), which also provides energy and methyl to promote choline synthesis. Choline reacts with liver fat to produce lecithin, which promotes the decomposition of liver fat. It participates in the formation of lipoproteins and reduces fat accumulation in the liver. More |
660-27-5 | 14 | |
| Sodium gluconateIngredients |
No specific pharmacological effects were mentioned. More |
527-07-1 | 12 |
Indication
Liver-protecting medicine. Used for fatty liver, intrahepatic cholestasis, and general liver dysfunction. Used for acute and chronic hepatitis, hepatomegaly, and early cirrhosis.
Usage and Dosage
Intramuscular injection: 40 mg (one vial) at a time, 1 to 2 times a day, dissolved in an appropriate amount of water for injection. Intravenous injection: 40 mg (one vial) at a time, 1 to 2 times a day, dissolved in an appropriate amount of water for injection. Intravenous drip: 40 to 80 mg (1 to 2 vials) at a time, 1 to 2 times a day, dissolved in an appropriate amount of water for injection, and diluted to an appropriate amount (50 ml to 100 ml) with 5% or 10% glucose injection or 0.9% sodium chloride injection. Please follow the doctor's advice for the course of treatment.
Adverse Reactions
Occasionally, you may experience dizziness, thirst, loss of appetite, etc., but these symptoms may disappear on their own.
Precautions
People who are allergic to this product are prohibited from using it. If an allergic reaction occurs, the symptoms will disappear after stopping the drug.
Drug Interactions
There are no special contraindications.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
Each vial contains 40mg of diisopropylamine dichloroacetate and 38mg of sodium gluconate
Manufacturer
Jiangsu Huatai Chenguang Pharmaceutical Co., Ltd.
-
Founded in:
2010-07-30 -
Address:
Building 17, No. 12, Xinglin Road, Taizhou City -
Tax NO.:
913212915592502469 -
Registered Funds:
90.350805 yuan -
Website:
-
Email: